CD8A and melanoma: In a more refined immune-profiling strategy, Chi et al. screened 66 immune-cell subpopulations and identified four predictive subsets (CD8+ CD28+ T cells, CD3+ TCRαβ+ HLA-DR+ T cells, CD3+ TCRγδ+ HLA-DR+ T cells, and CD1c+ dendritic cells) to construct an immune risk score that effectively predicted PFS in melanoma patients treated with aPD-1 monotherapy [172].